ATARA BIOTHERAPEUTICS, INC. Operating Expenses
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Operating Expenses of $72.37 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2023-08-08
- ATARA BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2023-06-30 was $72.37M, a 13.55% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2023-03-31 was $76.24M, a 20.19% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2022-12-31 was $75.76M, a 24.95% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating expenses for the quarter ending 2022-09-30 was $89.08M, a 1.22% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating expenses for fiscal 2022 was $344.09M, a 4.63% decline from fiscal 2021.
- ATARA BIOTHERAPEUTICS, INC. operating expenses for fiscal 2021 was $360.80M, a 16.74% increase from fiscal 2020.
- ATARA BIOTHERAPEUTICS, INC. operating expenses for fiscal 2020 was $309.05M, a 4.52% increase from fiscal 2019.
- ATARA BIOTHERAPEUTICS, INC. operating expenses for fiscal 2019 was $295.68M, a 24.70% increase from fiscal 2018.
| Period end | Operating Expenses 3 month | Operating Expenses 4 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $72.37M 10-Q · filed 2023-08-08 | $148.62M 10-Q · filed 2023-08-08 | $224.38M derived: sum of 3 quarters · filed 2023-08-08 | $313.46M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | $76.24M 10-Q · filed 2023-05-08 | $152.00M derived: sum of 2 quarters · filed 2023-05-08 | $241.09M derived: sum of 3 quarters · filed 2023-05-08 | $324.80M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-12-31 | $75.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $164.84M derived: sum of 2 quarters · filed 2023-02-08 | $248.55M derived: sum of 3 quarters · filed 2023-08-08 | $344.09M 10-K · filed 2023-02-08 | |
| 2022-09-30 | $89.08M 10-Q · filed 2022-11-08 | $172.79M derived: sum of 2 quarters · filed 2023-08-08 | $268.33M 10-Q · filed 2022-11-08 | $369.28M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-06-30 | $83.71M 10-Q · filed 2023-08-08 | $179.25M 10-Q · filed 2023-08-08 | $280.20M derived: sum of 3 quarters · filed 2023-08-08 | $370.38M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $95.53M 10-Q · filed 2023-05-08 | $196.49M derived: sum of 2 quarters · filed 2023-05-08 | $286.67M derived: sum of 3 quarters · filed 2023-05-08 | $374.54M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | $100.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $191.13M derived: sum of 2 quarters · filed 2023-02-08 | $279.00M derived: sum of 3 quarters · filed 2023-02-08 | $360.80M 10-K · filed 2023-02-08 | |
| 2021-09-30 | $90.18M 10-Q · filed 2022-11-08 | $178.05M derived: sum of 2 quarters · filed 2022-11-08 | $259.85M 10-Q · filed 2022-11-08 | $341.55M derived: sum of 4 quarters · filed 2023-02-08 | |
| 2021-06-30 | $87.87M 10-Q · filed 2022-08-08 | $169.67M 10-Q · filed 2022-08-08 | $251.37M derived: sum of 3 quarters · filed 2023-02-08 | $326.07M derived: sum of 4 quarters · filed 2023-02-08 | |
| 2021-03-31 | $81.80M 10-Q · filed 2022-05-05 | $163.49M derived: sum of 2 quarters · filed 2023-02-08 | $238.20M derived: sum of 3 quarters · filed 2023-02-08 | $316.15M derived: sum of 4 quarters · filed 2023-02-08 | |
| 2020-12-31 | $81.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $156.40M derived: sum of 2 quarters · filed 2023-02-08 | $234.35M derived: sum of 3 quarters · filed 2023-02-08 | $309.05M 10-K · filed 2023-02-08 | |
| 2020-09-30 | $74.71M 10-Q · filed 2021-11-04 | $152.66M derived: sum of 2 quarters · filed 2021-11-04 | $227.35M 10-Q · filed 2021-11-04 | $307.05M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $77.95M 10-Q · filed 2021-08-09 | $152.65M 10-Q · filed 2021-08-09 | $232.35M derived: sum of 3 quarters · filed 2022-02-28 | $304.90M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $74.70M 10-Q · filed 2021-05-04 | $154.40M derived: sum of 2 quarters · filed 2022-02-28 | $226.95M derived: sum of 3 quarters · filed 2022-02-28 | $302.49M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $79.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $152.25M derived: sum of 2 quarters · filed 2022-02-28 | $227.79M derived: sum of 3 quarters · filed 2022-02-28 | $295.68M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $72.56M 10-Q · filed 2020-11-09 | $148.09M derived: sum of 2 quarters · filed 2020-11-09 | $215.98M 10-Q · filed 2020-11-09 | $297.80M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $75.53M 10-Q · filed 2020-08-05 | $143.43M 10-Q · filed 2020-08-05 | $225.24M derived: sum of 3 quarters · filed 2021-03-01 | $285.46M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $67.89M 10-Q · filed 2020-05-06 | $149.71M derived: sum of 2 quarters · filed 2021-03-01 | $209.93M derived: sum of 3 quarters · filed 2021-03-01 | $262.55M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $81.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $142.04M derived: sum of 2 quarters · filed 2021-03-01 | $194.66M derived: sum of 3 quarters · filed 2021-03-01 | $237.11M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $60.22M 10-Q · filed 2019-11-07 | $112.84M derived: sum of 2 quarters · filed 2019-11-07 | $155.29M 10-Q · filed 2019-11-07 | $191.10M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $52.62M 10-Q · filed 2019-08-08 | $95.08M 10-Q · filed 2019-08-08 | $130.88M derived: sum of 3 quarters · filed 2020-02-27 | $162.54M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $42.45M 10-Q · filed 2019-05-09 | $78.25M derived: sum of 2 quarters · filed 2020-02-27 | $109.91M derived: sum of 3 quarters · filed 2020-02-27 | $137.82M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $35.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $67.46M derived: sum of 2 quarters · filed 2020-02-27 | $95.37M derived: sum of 3 quarters · filed 2020-02-27 | $121.53M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $31.66M 10-Q · filed 2018-11-06 | $59.57M derived: sum of 2 quarters · filed 2018-11-06 | $85.73M 10-Q · filed 2018-11-06 | $104.48M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | $27.91M 10-Q · filed 2018-08-01 | $54.07M 10-Q · filed 2018-08-01 | $72.82M derived: sum of 3 quarters · filed 2019-02-26 | $98.77M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | $26.16M 10-Q · filed 2018-05-08 | $44.91M derived: sum of 2 quarters · filed 2019-02-26 | $70.86M derived: sum of 3 quarters · filed 2019-02-26 | $90.34M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | $18.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $44.70M derived: sum of 2 quarters · filed 2019-02-26 | $64.18M derived: sum of 3 quarters · filed 2019-02-26 | $81.24M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $25.94M 10-Q · filed 2017-11-09 | $45.43M derived: sum of 2 quarters · filed 2017-11-09 | $62.49M 10-Q · filed 2017-11-09 | $84.26M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $19.48M 10-Q · filed 2017-08-07 | $36.55M 10-Q · filed 2017-08-07 | $58.32M derived: sum of 3 quarters · filed 2018-02-27 | $70.58M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $17.06M 10-Q · filed 2017-05-04 | $38.83M derived: sum of 2 quarters · filed 2018-02-27 | $51.09M derived: sum of 3 quarters · filed 2018-02-27 | $66.20M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | $21.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $34.03M derived: sum of 2 quarters · filed 2018-02-27 | $49.14M derived: sum of 3 quarters · filed 2018-02-27 | $58.45M 10-K · filed 2018-02-27 | |
| 2015-09-30 | $12.26M 10-Q · filed 2016-11-04 | $27.37M derived: sum of 2 quarters · filed 2016-11-04 | $36.68M 10-Q · filed 2016-11-04 | $47.27M derived: sum of 4 quarters · filed 2017-03-09 | |
| 2015-06-30 | $15.11M 10-Q · filed 2016-08-08 | $24.42M 10-Q · filed 2016-08-08 | $35.02M derived: sum of 3 quarters · filed 2017-03-09 | $40.96M derived: sum of 4 quarters · filed 2017-03-09 | |
| 2015-03-31 | $9.31M 10-Q · filed 2016-05-06 | $19.91M derived: sum of 2 quarters · filed 2017-03-09 | $25.86M derived: sum of 3 quarters · filed 2017-03-09 | $30.39M derived: sum of 4 quarters · filed 2017-03-09 | |
| 2014-12-31 | $10.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $16.55M derived: sum of 2 quarters · filed 2017-03-09 | $21.08M derived: sum of 3 quarters · filed 2017-03-09 | $28.16M 10-K · filed 2017-03-09 | |
| 2014-09-30 | $5.95M 10-Q · filed 2015-11-06 | $10.48M derived: sum of 2 quarters · filed 2015-11-06 | $17.56M 10-Q · filed 2015-11-06 | $20.98M derived: sum of 4 quarters · filed 2016-03-04 | |
| 2014-06-30 | $4.53M 10-Q · filed 2015-08-07 | $11.61M 10-Q · filed 2015-08-07 | $15.03M derived: sum of 3 quarters · filed 2016-03-04 | $17.58M derived: sum of 4 quarters · filed 2016-03-04 | |
| 2014-03-31 | $7.08M 10-Q · filed 2015-05-11 | $10.49M derived: sum of 2 quarters · filed 2016-03-04 | $13.05M derived: sum of 3 quarters · filed 2016-03-04 | ||
| 2013-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | $5.97M derived: sum of 2 quarters · filed 2016-03-04 | $8.62M 10-K · filed 2016-03-04 | ||
| 2013-09-30 | $2.55M 10-Q · filed 2014-11-12 | $5.20M 10-Q · filed 2014-11-12 | |||
| 2012-12-31 | $4.09M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |